GE HealthCare Technologies Inc. has bought the last 50% of Nihon Medi-Physics Co., Ltd. This is a big milestone. (NMP) from Sumitomo Chemical, securing full ownership of the company. This acquisition lets NMP use its skills in making radiopharmaceuticals. These are key for single photon emission computed tomography (SPECT) and positron emission tomography (PET). They help in detecting and diagnosing diseases.
Kevin O’Neill, President & CEO of GE HealthCare’s PDx segment, shared his excitement about the acquisition. He said, “We are pleased to welcome Nihon Medi-Physics to GE HealthCare. This move boosts our presence in Japan, where our contrast media and medical devices are essential for imaging procedures across the country.” Japan is set to lead the $7 billion global molecular imaging market. It will also become a center of excellence for Asia. As part of GE HealthCare, NMP will help advance this vision. It will use its expertise and reach to support global innovators. These innovators aim to introduce next-generation radiopharmaceuticals in Japan and beyond.”
NMP, based in Tokyo, has played a key role in radiopharmaceuticals since 1973. The company offers GE HealthCare radiopharmaceuticals. These are used in imaging for neurology, cardiology, and oncology. In 2023, NMP reported revenues of 28.2 billion JPY (approximately $183 million). GE HealthCare got involved with NMP when it bought Amersham plc in 2004. This purchase gave GE a 50% stake in NMP before it fully acquired the company.
GE HealthCare believes the transaction will have no impact on Adjusted EPS in the first year. However, it expects it to boost EPS in the years that follow. Solomon Partners Securities, LLC was GE HealthCare’s financial advisor for this acquisition. It was first announced in December 2024.
Forward-Looking Statements
This announcement has forward-looking statements. You can spot them by words like “will,” “expect,” “may,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” and similar terms. These statements explain how the acquisition may impact the company, market conditions, and its growth strategy. Forward-looking statements come with risks and uncertainties. Many of these are beyond the Company’s control.
Factors that could cause actual results to differ materially include challenges in realizing anticipated benefits, higher-than-expected operational costs, and business disruptions, including impacts on relationships with employees, customers, and suppliers. For more risks, check the “Risk Factors” section in GE HealthCare’s Annual Report on Form 10-K. This report goes to the U.S. Securities and Exchange Commission. Future updates or changes will also be included there. The Company has no duty to change these statements unless the law requires it.
